The Renova Therapeutics executive team includes experienced biopharmaceutical leaders with expertise in cardiovascular gene therapy, drug development, regulatory affairs, product registration, finance and corporate communications.
CEO and Co-founder Dr. Reich, along with the company's scientific founder, was among the very first pioneers in gene therapy and has, since the inception of the technology, dedicated his career to the idea of restoring the health of people facing seemingly intractable diseases.
Jack W. Reich, Ph.D.
CEO and Co-Founder
Dr. Jack W. Reich has extensive experience in the field of gene therapy. He was a co-founder of the first gene therapy company, Viagene, which was acquired by Chiron. He went on to found Collateral Therapeutics, the first gene therapy company focused on cardiovascular disease, later acquired by Schering AG. Dr. Reich received a B.A. in Biology from Washington and Jefferson College, a B.S. in Pharmacy from Creighton University, an M.S. in Hospital Pharmacy Administration from Temple University and a Ph.D. in Pharmaceuticals – International Pharmaceutical Administration from Temple University.
Roy Cosan is a 32-year veteran of Johnson & Johnson (J&J), where he was Vice President of New Product Development and, in that role, launched a $billion+ product for schizophrenia, as well as a leading treatment for dementia. He was also a VP with the J&J Development Corporation, the venture capital arm of J&J, where he invested in 19 companies and was a director on 11 boards. Mr. Cosan is Member of the Cancer Prevention & Research Institute of Texas (CPRIT) Product Development Review Council and a product development reviewer, in which he plays a role in advising, guiding and determining funding for cancer research projects in Texas. He holds a B.B.A. with a concentration in marketing from Western Michigan University.
Catherine Bovenizer, CPA
Chief Financial Officer
Catherine Bovenizer, CPA, has 20 years of experience in financial management for a variety of public and closely held biotech and software companies. Most recently, Ms. Bovenizer was the Vice President of Finance and Chief Accounting Officer at Apricus Biosciences. In this role, she oversaw the team responsible for full-cycle accounting, audit management, accounting policy and procedure implementation, SEC reporting, human resources and IT/facilities, along with supporting investor relations. Prior to Apricus, she held roles of increasing responsibility at Ambit Biosciences, Senomyx, Ligand Pharmaceuticals and GeneFormatics. She began her career at Coopers & Lybrand. Ms. Bovenizer graduated magna cum laude from Claremont McKenna College with a B.A. in Economics, Accounting and Literature.
Jennifer Spinella, MT(ASCP), RAC
Executive VP, Regulatory Affairs & Quality Assurance
Jennifer Spinella has more than 20 years of hands-on regulatory experience, from IND through registration with drugs, devices, diagnostics, biologics and gene therapy products. Most recently, she was Vice President, Regulatory Affairs and Quality Assurance for Rare Disease Therapeutics, Inc. Ms. Spinella has held multiple VP- and director-level regulatory positions at various companies. Prior to working in the pharmaceutical industry, she was a neonatal biochemist for eight years at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. Ms. Spinella earned her B.S. in Medical Technology from the University of Nebraska College of Medicine. She obtained her Regulatory Affairs Certificate (RAC) from the Regulatory Affairs Professional Society in 2000.
Richard McCloskey, MD
Executive VP, Clinical Development
Dr. Richard ‘Mac’ McCloskey oversees all aspects of clinical development for Renova Therapeutics. An author of more than 100 peer-reviewed papers and editorials as well as three books, Dr. McCloskey has led an illustrious career in medical research and clinical practice. He has directed registration trials for Hoffman LaRoche and Centocor and was, most recently, Vice President of Scientific Affairs at Johnson & Johnson Development Corporation as well as a scientific adviser to Endo Pharmaceuticals. Dr. McCloskey received a master’s in microbiology and an M.D. from the University of Rochester and completed his medical training at Duke University and the National Institutes of Health. He has been on the faculty of the University of Texas, the University of Pennsylvania and Jefferson Medical College, and he is an emeritus fellow of the American College of Physicians and the Infectious Disease Society of America.
Waldemar Radziszewski, MD, Ph.D.
Executive VP, Translational Research
Before joining Renova Therapeutics, Dr. Radziszewski served as Vice President, Development Unit Immunology, and Site Head, Biopharmaceuticals Clinical Development, at Sandoz. He spent 18 years in various senior leadership positions within Merck Research Laboratories and later Janssen R&D, managing clinical operations and multiple early- and late-stage clinical development projects with small molecules and therapeutic proteins and peptides in diverse therapeutic areas. Dr. Radziszewski received both his M.D. and his Ph.D. from Nicolas Copernicus Academy of Medicine in Krakow, Poland, now known as Jagiellonian University Medical College. He completed a Fogarty Foundation Post-Doctoral Fellowship in pharmacology at the Department of Molecular and Clinical Pharmacology, UCLA School of Medicine. He then trained in Clinical and Anatomical Pathology at UCLA Medical Center in Los Angeles.
Peter Gengo, Ph.D.
VP, Preclinical Research and Pharmacology
An accomplished biochemical analytical pharmacologist with extensive knowledge of drug discovery and early drug development, Dr. Peter Gengo has more than 30 years of research and leadership experience, most recently in the Cardiovascular & Metabolic Disease unit at Merck & Co. Dr. Gengo also spent several years with Johnson & Johnson companies, including Janssen Pharmaceuticals as Scientific Director and Research Fellow. Dr. Gengo earned his Ph.D. at the University of Buffalo, graduating summa cum laude. He graduated magna cum laude from the State University of New York with a B.S. in Biology. He received a Medical Technology Degree & License (MT, ASCP) at the School of Medical Technology at Rochester General Hospital in Rochester, NY.
Executive Director of Communications & Operations
Senka Hadzimuratovic leads the company’s external communications and operations efforts. Previously, Ms. Hadzimuratovic held roles of increasing responsibility at Novartis, most recently as Associate Director of Equity Brands and External Communications for Novartis Consumer Health, managing media relations and overseeing communication efforts for 150+ over-the-counter brands worldwide. Ms. Hadzimuratovic began her career with MESA Research Group, a strategic management consulting firm. She holds a Bachelor of Science in Journalism from Northwestern University Medill School of Journalism.